Physician profile
Ujagger Dhillon
NPI 1518054808
$7,328.21
in general payments reported to CMS, 2019-2025
35 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $233 · 2021: $1,060 · 2022: $1,243 · 2023: $1,178 · 2024: $983 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,757.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,796.86 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,278.90 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $942.02 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $441.56 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $401.70 | 2019-2021 | |
| Ardelyx, INC. | $281.83 | 2022-2025 | Ibsrela |
| Celgene Corporation | $249.30 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $247.07 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $226.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $208.86 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $174.71 | 2019-2023 | Ocaliva |
| Boston Scientific Corporation | $114.85 | 2019-2023 | Autotome Rx 49 |
| Shionogi INC | $111.01 | 2019-2020 | |
| Daiichi Sankyo INC. | $104.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $101.89 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $73.11 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $56.63 | 2022-2023 | Rebyota |
| Capsovision, INC. | $55.36 | 2025 | Capsocam Plus |
| Alfasigma USA, INC. | $45.49 | 2021-2022 | |
| Redhill Biopharma INC. | $37.23 | 2021 | |
| Qol Medical, LLC | $35.26 | 2019-2022 | |
| Pfizer INC. | $33.48 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $30.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.08 | 2022 | |
| Allergan, INC. | $26.76 | 2019 | |
| Lilly USA, LLC | $26.30 | 2025 | Omvoh |
| Novo Nordisk INC | $26.11 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $25.84 | 2021 | |
| Orphalan INC | $25.05 | 2025 | Cuvrior |
| Genzyme Corporation | $24.22 | 2023 | |
| Aimmune Therapeutics, INC. | $24.16 | 2024 | |
| Lucid Diagnostics INC. | $21.64 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $21.54 | 2022 | |
| Echosens North America, INC. | $19.07 | 2023 | Fibroscan |
| Concordia Pharmaceuticals INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ujagger Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.